Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: No correlation to peroxide generation

被引:54
作者
Scheiber-Mojdehkar, B
Lutzky, B
Schaufler, R
Sturm, B
Goldenberg, H
机构
[1] Med Univ Vienna, Dept Med Chem, A-1090 Vienna, Austria
[2] Wilheminenspital, Dept Nephrol & Dialysis, Vienna, Austria
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2004年 / 15卷 / 06期
关键词
D O I
10.1097/01.ASN.0000130149.18412.56
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Intravenous iron (iv.Fe) is used to optimize response to recombinant human erythropoietin (r-HuEPO) in ESRD, but no consensus exists with respect to the best regimen to avoid transferrin "oversaturation," oxidative stress, and the occurrence of non-transferrin-bound iron (NTBI). Iv.Fe was stopped for 1 wk in 35 hemodialysis (HD) patients who were routinely receiving iv.Fe and r-HuEPO. The iv.Fe group received 100 mg of ferric saccharate (Venofer) at the end of the first HD session, whereas the time-control group was treated under the same conditions but received no iv.Fe. Serum samples were taken before the first HD session, immediately and 60 min after iv.Fe administration, and before the next HD session. Sera were analyzed for NTBI and peroxides; transferrin saturation was analyzed by urea-PAGE and Western blot. In an in vitro model system with HepG2 cells, the effects of ESRD serum on the labile iron pool (LIP) were assayed using the fluorescence calcein assay. NTBI significantly increased after iv.Fe-administration and returned to baseline values before the next HD-session. There was a shift from apo- to monoferric transferrin, but no "oversaturation" of transferrin after iv.Fe-treatment. Peroxides increased in both groups after HD. Hemodialysis decreased bioavailable iron for the LIP in HepG2-cells, whereas serum of iv.Fe-treated HD patients highly increased the LIP in these cells. A total of 100 mg of iv.Fe led to NTBI generation but not to an oversaturation of transferrin. Peroxide concentrations significantly increased during HD but were not correlated to iv.Fe administration and seemed to result from other sources of oxidative stress related to HD. NTBI can enter liver cells and increase the potentially harmful LIP.
引用
收藏
页码:1648 / 1655
页数:8
相关论文
共 49 条
[2]  
BANYAI S, 1998, J AM SOC NEPHROL, V9, P199
[3]   Parenteral iron therapy: Safety and efficacy [J].
Besarab, A .
SEMINARS IN DIALYSIS, 1999, 12 (04) :237-242
[4]   The importance of non-transferrin bound iron in disorders of iron metabolism [J].
Breuer, W ;
Hershko, C ;
Cabantchik, ZI .
TRANSFUSION SCIENCE, 2000, 23 (03) :185-192
[5]   IRON ACQUIRED FROM TRANSFERRIN BY K562 CELLS IS DELIVERED INTO A CYTOPLASMIC POOL OF CHELATABLE IRON(II) [J].
BREUER, W ;
EPSZTEJN, S ;
CABANTCHIK, ZI .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (41) :24209-24215
[6]   The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation [J].
Breuer, W ;
Ronson, A ;
Slotki, IN ;
Abramov, A ;
Hershko, C ;
Cabantchik, ZI .
BLOOD, 2000, 95 (09) :2975-2982
[7]   Risk of bacterial infection in patients under intravenous iron therapy: Dose versus length of treatment [J].
Canziani, MEF ;
Yumiya, ST ;
Rangel, EB ;
Manfredi, SR ;
Neto, MC ;
Draibe, SA .
ARTIFICIAL ORGANS, 2001, 25 (11) :866-869
[8]   The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients [J].
Cavdar, C ;
Temiz, AE ;
Yeniçerioglu, Y ;
Çaliskan, S ;
Çelik, A ;
Sifil, A ;
Önvural, B ;
Camsari, T .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2003, 37 (01) :77-82
[9]   Intravenous iron sucrose: Establishing a safe dose [J].
Chandler, G ;
Harchowal, J ;
Macdougall, IC .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (05) :988-991
[10]  
COLLINS A, 1997, J AM SOC NEPHROL, V8, P190